A proposed class action filed Thursday in Manhattan federal court accused Pfizer Inc. of misleading consumers about the health risks associated with the over-the-counter heartburn medicine Zantac.

The lawsuit targeted the New York-based drugmaker over its former production of the medicine, which includes NDMA, an organic chemical that has been linked to certain forms of cancer. According to the filing, Pfizer manufactured Zantac from 2000 to 2006, but never listed NDMA as an ingredient or disclosed the chemical’s cancer-causing properties.